NYSE American - Delayed Quote USD

NanoViricides, Inc. (NNVC)

1.1000 -0.0750 (-6.38%)
At close: April 19 at 4:00 PM EDT
1.1000 0.00 (0.00%)
After hours: April 19 at 7:24 PM EDT

Key Executives

NanoViricides, Inc.

1 Controls Drive
Shelton, CT 06484
United States
203 937 6137 https://www.nanoviricides.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
7

Description

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Corporate Governance

NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
NanoViricides, Inc. Earnings Call

Related Tickers

BVNRY Bavarian Nordic A/S
6.96
+0.51%
 
CANF Can-Fite BioPharma Ltd.
1.9800
+0.51%
 
BRNS Barinthus Biotherapeutics plc
2.5100
-5.99%
 
OKYO OKYO Pharma Limited
1.4027
-1.91%
 
HOTH Hoth Therapeutics, Inc.
1.1955
+1.31%
 
ARMP Armata Pharmaceuticals, Inc.
2.6650
+4.51%
 
IPIX Innovation Pharmaceuticals Inc.
0.0042
-58.42%
 
ELAB Elevai Labs, Inc.
0.5720
-1.38%
 
COCP Cocrystal Pharma, Inc.
1.5299
+4.07%
 
SLGL Sol-Gel Technologies Ltd.
0.9400
-0.49%